Article info
PDFResponse
Responding to objections to gatekeeping for hormone replacement therapy
- Correspondence to Toni C Saad, Hafen-Y-Coed, University Hospital of Llandough, Penlan Road, Llandough, Penarth CF64 2XX, Cardiff and Vale University Health Board, Cardiff, UK; ToniSaad{at}doctors.org.uk
Citation
Responding to objections to gatekeeping for hormone replacement therapy
Publication history
- Received August 30, 2019
- Revised September 19, 2019
- Accepted September 26, 2019
- First published October 31, 2019.
Online issue publication
December 06, 2019
Article Versions
- Previous version (3 December 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Reply to ‘Hormone replacement therapy: informed consent without assessment?’
- Hormone replacement therapy: informed consent without assessment?
- Gatekeeping hormone replacement therapy for transgender patients is dehumanising
- Current management of male-to-female gender identity disorder in the UK
- Integrity and rights to gender-affirming healthcare
- Doctors are failing to help people with gender dysphoria
- Forever young? The ethics of ongoing puberty suppression for non-binary adults
- Validity and reliability of the Thai version of the Utrecht Gender Dysphoria Scale-Gender Spectrum (UGDS-GS) in Thai youths and young adults with gender dysphoria
- Conversion therapies and access to transition-related healthcare in transgender people: a narrative systematic review
- Detransition needs further understanding, not controversy